Skip to main content Toggle menu Compare Search Sign in or Register Cart Search Search Shop All Sterile Products All Sterile Products IV Bags Syringes Vials Non-Sterile Products All Non-Sterile Products Oral Syringes Topicals Schedule II Schedule III-V Schedule VI Contact Us Blog Sign in or Register Home Sterile Products Vials Glutathione Injection 200 mg/mL 30 mL fill 30R Vial (Preservative-free) Glutathione Injection 200 mg/mL 30 mL fill 30R Vial (Preservative-free) Log in for pricing Write a Review Write a Review Close Glutathione Injection 200 mg/mL 30 mL fill 30R Vial (Preservative-free) Rating Required Select Rating 1 star (worst) 2 stars 3 stars (average) 4 stars 5 stars (best) Name Required Email Required Review Subject Required Comments Required SKU: ANVX-0510-30 UPC: NDC: 82396-0510-31 BUD from Date of Compounding: 90-days REF Current Stock: Add to Wish List Create New Wish List Facebook Email Print X Pinterest Close Related Products Quick view Glutathione Injection 200 mg/mL 30 mL fill 30R Vial (Preserved) Log in for pricing Quick view NAD+ (Nicotinamide Adenine Dinucleotide) Injection 200 mg/mL 6 mL fill 10R Vial Log in for pricing Quick view NAD+ (Nicotinamide Adenine Dinucleotide) Injection 200 mg/mL 10 mL fill 10R Vial Log in for pricing Quick view NAD+ (Nicotinamide Adenine Dinucleotide) Injection 200 mg/mL 2.5 mL fill 6R Vial Log in for pricing Quick view NAD+ (Nicotinamide Adenine Dinucleotide) Injection 200 mg/mL 5 mL fill 6R Vial Log in for pricing Close

Star ingredients: Helianthus Annuus (Sunflower) Seed Oil, Olea Europaea (Olive) Fruit Oil, Simmondsia Chinensis (Jojoba) Seed Oil, Ascorbic Acid, Glutathione
Future of Peptide Therapy and Regulation In the next 6-24 months, more physician-led options for peptide access are expected to become available, and it is essential for individuals to have a good relationship with their physician and for physicians to get educated on peptides to ensure safe and effective use 12m0s
Sleep: Aim for 79 hours to support the bodys natural repair processes
5i) and western blot analysis (Extended Data Fig
As of September 2023 it is on the FDA Category 2 list of bulk drug substances that may not be compounded, and a PCAC review is scheduled for July 2026 under the name Emideltide